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Lipids and lipid nanoparticles are extensively employed as oral-delivery systems for drugs and other active ingredients. These
have been exploited for many features in the ﬁeld of pharmaceutical technology. Lipids usually enhance drug absorption in the
gastrointestinal tract (GIT), and when formulated as nanoparticles, these molecules improve mucosal adhesion due to small
particle size and increasing their GIT residence time. In addition, lipid nanoparticles may also protect the loaded drugs from
chemical and enzymatic degradation and gradually release drug molecules from the lipid matrix into blood, resulting in improved
therapeutic proﬁles compared to free drug. Therefore, due to their physiological and biodegradable properties, lipid molecules
may decrease adverse side eﬀects and chronic toxicity of the drug-delivery systems when compared to other of polymeric nature.
This paper highlights the importance of lipid nanoparticles to modify the release proﬁle and the pharmacokinetic parameters of
drugs when administrated through oral route.
1.Introduction
The use of lipid particles in pharmaceutical technology has
been reported for several years. The ﬁrst approach of using
lipid microparticles was described by Eldem et al. [1], re-
porting the production by high-speed stirring of a melted
lipid phase in a hot surfactant solution obtaining an emul-
sion. Solid microparticles are formed when this emulsion is
cooled to room temperature, and the lipid recrystallizes. The
obtained products were called “lipid nanopellets”, and they
havebeendevelopedfororaladministration[2].Lipospheres
weredescribedbyDombapplyingasonicationprocess[3–5].
To overcome the drawbacks associated to the traditional col-
loidal systems [6], such as emulsions [7], liposomes [8], and
polymeric nanoparticles [9], solid lipid nanoparticles (SLN)
[10, 11] have been developed for similar purposes [12].
SLN are biocompatible and biodegradable and have been
used for controlled drug delivery and speciﬁc targeting.
These colloidal carriers consist of a lipid matrix that should
be solid at both room and body temperatures, having a mean
particle size between 50nm and 1000nm [13, 14].
A clear advantage of the use of lipid particles as drug-
carrier systems is the fact that the matrix is composed of
physiological components, that is, excipients with generally
recognized as safe (GRAS) status for oral and topical
administration, which decreases the cytotoxicity. SLN have
been already tested as site-speciﬁc carriers particularly for
drugs that have a relatively fast metabolism and are quickly
eliminated from the blood, that is, peptides and proteins
[15].
The cytotoxicity of SLN can be attributed to nonionic
emulsiﬁers and preservative compounds which are used in2 Journal of Drug Delivery
the production of these systems [16]. SLN prepared up to
concentrations of 2.5% lipid do not exhibit any cytotoxic
eﬀects in vitro [17]. Even concentrations higher than 10% of
lipid have been shown a viability of 80% in culture of human
granulocytes[18].Incontrast,somepolymericnanoparticles
showed complete cell death at concentrations of 0.5%. In
addition, a high loading capacity for a broad range of drugs
can be achieved, especially if they have lipophilic properties
[12, 19].
Due to their physiological and biodegradable properties,
SLN have been tested for several administration routes [20,
21], including the oral [22, 23]a n dp e r o r a l[ 24, 25]r o u t e s .
SLN can be obtained by exchanging the liquid lipid (oil)
of the o/w nanoemulsions by a solid lipid [19]. In general, a
solid core oﬀers many advantages in comparison to a liquid
core [26]. Emulsions and liposomes usually show lack of
protection of encapsulated drugs, and drug release as a burst
(emulsions)ornoncontrolled(fromliposomes).SLNpossess
a solid lipid matrix identical to polymeric nanoparticles.
In addition, SLN are of low cost [27], the excipients and
production lines are relatively cheap, and the production
costs are not much higher than those established for the
production of parenteral emulsions [28].
At the turn of the millennium, modiﬁcations of SLN,
the so-called nanostructured lipid carriers (NLCs), have
been introduced to the literature, and these NLC represent
nowadaysthesecondgenerationoflipidnanoparticles.These
carrier systems overcome observed limitations of conven-
tional SLN [29]. The main diﬀerence between SLN and NLC
is the fact that the concept of these latter is performed
by nanostructuring the lipid matrix, in order to increase
the drug loading and to prevent its leakage, giving more
ﬂexibility for modulation of drug release. This approach is
achieved by mixing solid lipids with liquid lipids in NLC
instead of highly puriﬁed lipids with relatively similar
molecules in SLN. This mixture has to be solid at least at
40◦C. The result is a less-ordered lipid matrix with many
imperfections, which can accommodate a higher amount of
drug [11].
2. Role of LipidsinOral Delivery
A limiting factor for in vivo performance of poorly water-
soluble drugs for oral administration is their resistance of
being wetted and dissolved into the ﬂuid in the GIT (apart
from potential drug degradation in the gut). Thus, the
increase in the dissolution rate of poorly water-soluble drugs
is relevant for optimizing bioavailability. Over the last 10
years, poorly water-soluble compounds are formulated in
lipid nanoparticles for drug administration [30]. The fea-
tures of lipid nanoparticles for oral and peroral delivery are
related with their adhesive properties. Once adhered to the
GIT wall, these particles are able to release the drug exactly
where it should be absorbed. In addition, the lipids are
known to have absorption-promoting properties not only
for lipophilic drugs, such as Vitamin E, repaglinide [22], and
puerarin [23].
Hydrophilic drugs can also be incorporated in SLN; nev-
ertheless, the aﬃnity between the drug and the lipid needs to
be analysed. Therefore, loading hydrophilic drugs in SLN is
a challenge due to the tendency of partitioning the encapsu-
lated molecules in the water during the production process
of nanoparticles [31]. Successful examples are zidovudine
[31],insulin[32],tretinoin[33],anddiminazene[34].There
are even diﬀerences in the lipid absorption enhancement
depending on the structure of the lipids. For example,
medium-chain triglycerides (MCT) lipids are more eﬀective
than long-chain triglycerides (LCT) [35]. Basically, the body
is taking up the lipid and the solubilized drug at the same
time. It can be considered as a kind of “Trojan horse” eﬀect
[36, 37].
Oral administration of SLN is possible as aqueous dis-
persion [38] or alternatively transformed into a traditional
dosage forms such as tablets, pellets, capsules, or powders in
sachets [25, 39]. For this route, all the lipids and surfactants
used in traditional dosage forms can be exploited. In addi-
tion, all compounds of GRAS status or accepted GRAS status
canbeemplo y edasw ellasfr omthefoodindustry[40].Since
the stomach acidic environment and high ionic strength
favour the particle aggregation, aqueous dispersions of lipid
nanoparticles might not be suitable to be administered as
dosage form. In addition, the presence of food will also have
a high impact on their performance [41].
The packing of SLN in a sachet for redispersion in water
or juice prior to administration will allow an individual dos-
ing by volume of the reconstituted SLN. For the production
oftablets,theaqueousSLNdispersionscanbeusedinsteadof
a granulation ﬂuid in the granulation process. Alternatively,
SLN can be transferred to a powder (by spray-drying or
lyophilization) and added to the tabletting powder mixture.
In both cases, it is beneﬁcial to have a higher solid content
to avoid the need of having to remove too much water. For
cost reasons, spray drying might be the preferred method
for transforming SLN dispersions into powders, with the
previous addition of a protectant [42].
For the production of pellets, the SLN dispersion can be
used as a wetting agent in the extrusion process. SLN pow-
ders can also be used for the ﬁlling of hard gelatine capsules.
Alternatively, SLN can be produced directly in liquid PEG
600 and put into soft gelatine capsules. Advantages of the use
of SLN for oral and peroral administration are the possibility
of drug protection from hydrolysis, as well as the possible
increase of drug bioavailability. Prolonged plasma levels has
also been postulated due to a controlled, optimized released
[22] in combination with general adhesive properties of
small particles [43] .T h ea d v a n t a g eo fc o l l o i d a ld r u gc a r r i e r s
described above is that they are generally linked to their
size in the submicron range. Therefore, the preservation of
particle size of colloidal carrier systems after peroral admi-
nistration is a crucial point. The gastric environment (ionic
strength, low pH) may destabilize the SLN and potentially
lead to aggregation. However, it is possible to produce stable
SLN dispersions by optimizing the surfactant/mixture for
each lipid in vitro [44].
The drug release from SLN in the GIT is also dependent
on the lipase/colipase activity for the GIT digestion of the
lipid matrix. The lipase/colipase complex leads to a degra-
dation of food lipids as a prestep of the absorption. In vitroJournal of Drug Delivery 3
degradation assay based on pancreas lipase/colipase complex
have been developed to obtain basic information about
the degradation velocity of SLN as a function of lipid and
surfactant used in the production process [45, 46].
Lipid nanoparticles show great promise to enhance oral
bioavailability of some of the most poorly soluble drugs.
The physical/chemical characteristics of lipid particulate
systems are highly complex due to the existence of a variety
of lipid assembly morphologies, the morphology-dependent
solubility of drug, the interconversion of assembly morphol-
ogy as a function of time and chemical structure, and the
simultaneous lipid digestion [47].
3. LipidNanoparticles asDrug Carriers
Lipid nanoparticles show interesting features concerning
therapeutic purposes. Their main characteristic is the fact
that they are prepared with physiologically well-tolerated
lipids [48]. During the last ten years, diﬀerent substances
have been entrapped into lipid nanoparticles (Table 1),
ranging from lipophilic [23, 49] and hydrophilic molecules,
including labile compounds, such as proteins and peptides
[50].
3.1. Lipid Materials for Oral Administration. The term lipid
is used here in a broader sense and includes triglycerides,
partial glycerides, fatty acids, steroids, and waxes. However,
it is required that matrix maintains the solid state at
room temperature, and for this purpose, the selection of
lipids is based on the evaluation of their polymorphic,
crystallinity, miscibility, and physicochemical structure [11].
Table 2 shows the main lipids employed for the preparation
of lipid nanoparticles.
Furthermore, the use of mono- and diglycerides as lipid
matrixcompositionmightincreasedrugsolubilitycompared
to highly pure lipids, such as monoacid triglycerides. Na-
turally occurring oils and fats comprise mixtures of mono-,
di-, and triglycerides, containing fatty acids of varying chain
length and degree of unsaturation [25, 86]. The melting
point of these lipids increases with the length of the fatty
acidchainanddecreaseswiththedegreeofunsaturation.The
chemical nature of the lipid is also important, because lipids
which form highly crystalline particles with a perfect lattice
(e.g., monoacid triglycerides) lead to drug expulsion during
storage time. Physicochemically stable lipid nanoparticles
will be obtained only when the right surfactant and adjusted
concentration have been employed [25].
3.2. Determination of Optimal Hydrophile-Lipophile Balance
(HLB)ValuesforLipidNanoparticlesDispersions. Emulsiﬁers
are essential to stabilize lipid nanoparticles dispersions and
prevent particle agglomeration [87]. The choice of the
ideal surfactant for a particular lipid matrix is based on
the surfactant properties such as charge, molecular weight,
chemical structure, and respective hydrophile-lipophile ba-
lance (HLB). All these properties aﬀects the stability of the
emulsion [10]. The HLB of an emulsiﬁer is given by the
balance between the size and strength of the hydrophilic and
the lipophilic groups. All emulsiﬁers consist of a molecule
that combines both hydrophilic and lipophilic groups.
Griﬃn[ 88] deﬁned the lipophilic emulsiﬁers as low HLB
values (below 9), and hydrophilic emulsiﬁers as high HLB
values (above 11). Those in the range of 9–11 are intermedi-
ate [89].
The HLB system is a useful method to choose the ideal
emulsiﬁer or blend of emulsiﬁers for the system, that is, if
its required an oil-in-water (o/w), water-in-oil (w/o) [90],
or a double (w/o/w) emulsion. Matching the HLB value of
the surfactant with the lipid will provide a suitable in vitro
performance [91]. Table 3 depicts the mainly surfactants
employed in the production of lipid nanoparticles.
Severino et al. [10] determined the HLB value for stearic
acid and stearic acid capric/caprylic triglycerides to reach
the best combination of surfactants (trioleate sorbitan and
polysorbate 80) to obtain a stable lipid nanoparticles emul-
sion. The HLB value obtained for stearic acid was 15 and
for stearic acid capric/caprylic triglycerides was 13.8. Sor-
b i t a nt r i o l e a t eh a sa nH L Bv a l u eo f1 . 8a n dp o l y s o r b a t e
80 of 15, when used in the ratio 10:90, respectively. The
surfactant mixtures prepared with diﬀerent ratios provided
well-deﬁned HLB values. Polysorbate 80 is often used in
combination with sorbitan trioleate due to their appropriate
compatibility attributed to the similar chemical structure
(samehydrocarbonchainlength)fortheproductionofstable
emulsions.
4.Biopharmaceutic and
PharmacokineticAspects
Pharmacokinetic behaviour of drugs loaded in lipid nano-
particles need to diﬀerentiate if the drug is present as the
released free form or as the associated form with lipid
nanoparticles [106]. However, the poor aqueous solubility
of some drugs turns diﬃcult the design of pharmaceutical
formulations and leads to variable bioavailability [107].
Xie et al. [108] reported a signiﬁcant increase in the
bioavailability and extended the systemic circulation of
oﬂoxacin formulated in SLN, which could be attributed to a
large surface area of the particles, improving the dissolution
rate and level of oﬂoxacin in the presence of GIT ﬂuids [109,
110], leading to shorter Tmax and higher peak plasma con-
centration.Inaddition,lipidnanoparticlesmayadheretothe
GIT wall or enter the intervillar spaces due to their small
particle size, increasing their residence time [111]. Moreover,
nanoparticles could protect the drug from chemical and
enzymatic degradation and gradually release drug from the
lipid matrix into blood, [112] resulting in a several-fold
increase mean residence time compared with native drug.
Han et al. [113] demonstrated that 5 oral doses of tilmicosin
loaded in lipid nanoparticles administered every 10 days
provided an equivalent therapeutic beneﬁt to 46 daily doses
of oral free drugs. In vitro release proﬁle demonstrated that
tilmicosin loaded in lipid nanoparticles followed a sustained
release proﬁle, and in vivo results showed that nanoparticles
remained eﬀective for a longer period of time, which was4 Journal of Drug Delivery
Table 1: Examples of drugs, miscellaneous active ingredients and macrocyclic skeletons incorporated into lipid nanoparticles.
Incorporated drug or
substance Lipid Advantageous System References
3 -Azido-3 -
deoxythymidine
palmitate
Trilaurin Stable after autoclaving, and can be
lyophilized and rehydrated SLN [51]
5-Fluorouracil Dynasa 114 and Dynasan
118
Prolonged release in simulated colonic
medium SLN [52]
Apomorphine
Glyceryl monostearate,
polyethylene glycol
monostearate
Enhanced the bioavailability in rats SLN [20]
Ascorbyl palmitate Imwitor 900 and Labraﬁl
M1944
Viscoelastic measurements is appropriate
for topical/dermal application NLC [53]
Baclofen Stearic acid Signiﬁcantly higher drug concentrations
in plasma SLN [54]
Benzyl nicotinate Dynasan 116 Increased oxygenation in the skin SLN [55]
Calcitonin Trimyristin Improvement of the eﬃciency of such
carriers for oral delivery of proteins SLN [56]
Camptothecin Monostearin and Soybean
Oil 788
Stable and high performance delivery
system NLC [57, 58]
Clozapine Trimyristin, tripalmitin,
and tristearin Improvement of bioavailability SLN [59]
Cyclosporin A glyceryl monostearate, and
glyceryl palmitostearate Controlled release SLN [60, 61]
Dexamethasone Compritol 888 ATO Drug delivery topical use SLN [62]
Diazepam Compritol ATO 888 and
Imwitor 900K Prolonged release SLN [63]
Doxorubicin Glyceryl caprate Enhanced apoptotic death SLN [64]
Gonadotropin release
hormone Monostearin Prolonged release SLN [65]
Hydrocortisone
Monoglyceride, chain
length of the fatty acid
moiety
SLN stable with release properties SLN [66]
Ibuprofen stearic acid, triluarin,
tripalmitin
Stable formulation and negligible cell
cytotoxicity SLN [67]
Idarubicin Emulsifying wax Potential to deliver anticancer drugs SLN [68]
Insulin
Stearic acid, octadecyl
alcohol, cetyl palmitate,
glyceryl monostearate,
glyceryl palmitostearate,
glyceryl tripalmitate,
glyceryl behenate
Promising for oral delivery of proteins SLN [50]
Ketoprofen mixture of beeswax and
carnauba wax
SLN with beeswax content exhibited
faster drug release as compared carnauba
wax
SLN [69]
Lopinavir Compritol 888 ATO Bioavailability enhanced SLN [70]
Nimesulide
Glyceryl behenate,
palmitostearate, glyceryl
tristearate
Sustained drug release SLN [71]
Penciclovir Glyceryl monostearate Provide a good skin targeting SLN [72]
Progesterone Monostearin, stearic acid
and oleic acid
Potential drug delivery system for oral
administration NLC [73, 74]
Repaglinide Glycerol monostearate and
tristearin
Toxicity study indicated that the SLN
were well tolerated SLN [22, 49]
Salbutamol sulphate Monostearin and PEG2000 Formulation accelerate release of
hydrophilic small molecule drugs SLN [75]
Tetracycline glyceryl monostearate and
stearic acid Sustained release SLN [76]Journal of Drug Delivery 5
Table 2: Lipids used for lipid nanoparticles production.
Lipids References
Triglycerides
Trimyristin (Dynasan 114) [11]
Tripalmitin (Dynasan 116) [77]
Tristearin (Dynasan 118) [11]
Mono, di and triglycerides mixtures
Witeposol bases [78]
Glyceryl monostearate (Imwitor 900) [22]
Glyceryl behenate (Compritol 888 ATO) [79]
Glyceryl palmitostearate (Precirol ATO 5) [80]
Waxes
Beeswax [81]
Cetyl palmitate [82]
Hard fats
Stearic acid [10]
Palmitic acid [83]
Behenic acid [84]
Other lipids
Miglyol 812 [11]
Paraﬃn[ 85]
Table 3: Emulsiﬁers used for the production of lipid nanoparticles.
Emulsiﬁers/coemulsiﬁers HLB References
Lecithin 4–9 [92, 93]
Poloxamer 188 29 [94]
Poloxamer 407 21.5 [56, 95]
Tyloxapol 13 [96]
Polysorbate 20 16.7 [92]
Polysorbate 60 14.9 [97]
Polysorbate 80 15 [10, 11]
Sodium cholate 18 [98]
Sodium glycocholate 14.9 [99]
Taurodeoxycholic acid sodium 13-14 [100]
Butanol and Butyric acid 7–9 [101]
Cetylpyridinium chloride ∼15 [102]
Sodium dodecyl sulphate 40 [103]
Sodium oleate 18 [99]
Polyvinyl alcohol 15–19 [104]
Cremophor EL 12–14 [105]
attributed to sustained release of the drug and also to
enhanced antibacterial activity by the SLN.
Pandita et al. [114] developed paclitaxel loaded in SLN
with the aim at improving the oral bioavailability of this
antineoplastic drug. In vitro studies of SLN formulation
exhibited an initial low burst eﬀect within 24h followed by a
slow and sustained release. Statistical analysis of in vivo
experiments concluded that the oral bioavailability of pacli-
taxel loaded in SLN was signiﬁcantly higher than the control
group.
Yuan et al. [115] produced stearic acid-SLN with a
ﬂuorescencemarkedforevaluationofinvivopathwaybyoral
administration. About 30% of SLN transport was eﬃcient,
where particles were absorbed following linear mechanism
in the GIT. The release proﬁle in plasma increased with the
increasing of dosage depicting two concentration peaks. The
ﬁrst peak of SLN in blood took place during 1-2h, attributed
to the fast uptake of SLN from the GIT into systematic
circulation. Drug concentration began to decrease attributed
to the uptake by and the distribution of SLN among
particular organs. The second peak occurred at about 6–8h,
andthemaximumconcentrationswerelowerthanthatofthe
ﬁrst peak.
5.Toxicology
Lipid nanoparticles are well tolerated in living systems, since
they are made from physiological compounds leading to
the metabolic pathways [22, 28]. For this purpose, studies
focusing on nanotoxicology comprise cytotoxicity and geno-
toxicity analysis [116]. However, such eﬀects often occur ﬁrst
at rather in high concentrations and the subtler eﬀects that
ariseatlowerconcentrations,withoutnecessarilycausingcell
death, also need to be considered. One the most important
eﬀect is DNA damage, since an increased genetic insta-
bility is associated with cancer development [117]. The
interaction with proteins and cells are an essential focus
in assessing and understanding compatibility and toxicity.
Cell and nanoparticle reactions of interest include cellular
uptake and processing of nanoparticle in various routes,
eﬀects on cell signalling, membrane perturbations, inﬂuence
on the cellular electron transfer cascades, production of
cytokines, chemokines, and reactive oxygen species (ROS),
transcytosisandintercellulartransport,generegulationovert
toxic reactivity, no observable toxicity, and cell necrosis or
apoptosis. In vitro c u l t u r eo fc e l ll i n e so rp r i m a r yc e l l so n
plastic plates are employed in a wide varieties of assays
and reﬂect the variety of possible physiologic responses to
nanoparticles in vivo and all possible cell processing routes
and natural reactions [118].
Silva et al. [119] studied the toxicity of SLN and risperi-
done loaded SLN with Caco-2 cells by (4,5-dimthylthiazol-
2-yl)2,5-diphenyl-tetrazolium bromide (MTT) assay. The
results suggest that all formulations evaluated are biocom-
patible with Caco-2 cells and well tolerated by the GIT.
Similar results have been reported elsewhere [120, 121]. This
test evaluates the mitochondrial function as a measurement
of cell viability, which allows the detection of dead cells
before they lose their integrity and shape. The amount of
viable cells after SLN exposure was performed by the MTT
assay with Caco-2 cell models, which are a well-established
in vitro model that mimics the intestinal barrier and is
often used to assess the permeability and transport of oral
drugs [122]. Other authors have also reported that SLN6 Journal of Drug Delivery
showbiocompatibility,whichincreasetheirattractivenessfor
drug-delivery applications [120].
6.MarketedProductsandCurrentStudies
Since early nineties, researchers turned their attention
to lipid nanoparticles because of their nontoxicity and
cost/eﬀectiveness relationship [12]. In spite of the advan-
tages,formulatingwithlipidnanoparticleshasbeensuﬀering
some drawbacks. Because of the GIT conditions, most of
promising drugs do not reach clinical trials. The stability of
particles must be comprehensively tested due to pH changes
and ionic strength as well as the drug release upon enzymatic
degradation [123]. Lipid nanoparticles absorption through
GIT occurs via transcellular (through M cells or enterocytes)
or paracellular (diﬀusion between cells). If the major drug
uptake occurs through M cells, the portal vein to the liver
is bypassed, resulting in higher drug concentrations to the
lymph rather than to plasma [124]. Despite the low number
of lipid nanoparticles formulations on the market for
drug delivery, Mucosolvan retard capsules (Boehringer-
Ingelheim) is a story of success [125]. Mucosolvan retard
capsules was the ﬁrst generation. It was produced by high-
speedstirringofameltedlipidphaseinahotsurfactantsolu-
tion obtaining an emulsion. This emulsion was then cooled
down to room temperature obtaining the so-called “lipid
nanopellets for oral administration” [126].
Successful in vivo studies also include rifampicin, iso-
niazid, and pyrazinamide that are used in tuberculosis
treatment. These drugs achieved higher bioavailability when
incorporated into SLN compared to the free solutions.
Rifampicin has poor cellular penetration which requires
high doses to reach eﬀective concentrations. Rifamsolin is a
rifampicin-loaded SLN under preclinical phase by AlphaRx.
The methodology employed for production is acceptable by
the regulatory agencies and has been addressed by various
papers and patents [127].
Poor water-soluble drugs, as camptothecin, vinpocetine,
and fenoﬁbrate, can have their solubilization improved if
incorporated into SLN [124, 128]. Another example is
insulin, commonly administered parenterally in the treat-
ment of diabetes mellitus. Injections are often painful and
must be administered daily, which result in low patient com-
pliance [129]. Unfortunately, oral administration of insulin,
produced by solvent emulsiﬁcation-evaporation method
based on a w/o/w double emulsion, has limitations such
as low bioavailability due to degradation in the stomach,
inactivation and degradation by proteolytic enzymes, and
low permeability across the intestinal epithelium because
of lack of lipophilicity and high molecular weight [124,
129]. The main advantages of incorporate insulin into SLN
would be the enhancement of transmucosal transport and
protection from the degradation in the GIT.
7. Conclusions
Lipidsandlipidnanoparticlesarepromisingfororalandper-
oral administration route for drugs, proteins, and peptides.
Theses matrices are able to promoting controlled release
of drugs in GIT and reducing absorption variability. In
addition, these matrices can be absorption as food lipids
together with drugs improving the bioavailability. These sys-
tems present several advantages, including drug protection
and excipients of GRAS status, which decreases the danger of
acute and chronic toxicity. In addition, the oral administra-
tion of lipids nanoparticles is possible as aqueous dispersion
or alternatively transformed into a traditional dosage forms
such as tablets, pellets, capsules, or powders in sachets.
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